PSMA-targeting compounds and uses thereof
Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.
1. A compound having the following chemical structure:
wherein Z is tetrazole or CO 2 Q; wherein each Q is independently selected from hydrogen or a protecting group, wherein the protecting group is selected from the group consisting of benzyl, p-methoxybenzyl, tertiary butyl, methoxymethyl, methoxyethoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl, benzyloxymethyl, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, and triphenylmethyl;
a is 1, 2, 3, or 4;
R is each independently H or C 1 -C 4 alkyl;
Y is —C(O)—;
V is —C(O)— or —NRC(S)—;
m is 1, 2, 3, 4, 5, or 6;
n is 1, 2, 3, 4, 5 or 6;
p is 0, 1, 2, or 3, and when p is 2 or 3, each R 1 may be the same or different;
R 1 is H, C 1 -C 6 alkyl, C 2 -C 12 aryl, or C 4 -C 16 alkylaryl
R 2 and R 3 are independently H, CO 2 H, or CO 2 R 4 , where R 4 is a C 1 -C 6 alkyl, C 2 -C 12 aryl, or C 4 -C 16 alkylaryl, wherein when one of R 2 and R 3 is CO 2 H or CO 2 R 4 , the other is H, and when p is 0, one of R 2 and R 3 is CO 2 R 4 , and the other is H; and
Ch is a chelating moiety, optionally including a chelated metal, wherein the chelating moiety is selected from the group consisting of:
and wherein + is the bond connecting the chelating moiety to the rest of the molecule.
2. A compound according to claim 1 , having a chelated metal, wherein the chelated metal is Tc, In, Ga, Y, Lu, Re, Cu, Ac, Bi, Pb, Sm, Sc, Co, Ho, Gd, Eu, Tb, or Dy.
3. A compound according to claim 1 selected from the group consisting of
4. A method of imaging one or more cells, organs or tissues by exposing the cell to or administering to an organism an effective amount of a compound according to claim 1 , where the compound includes a metal isotope suitable for imaging, and imaging the one or more cells, organs, or tissues.
5. A method of treating a tumor comprising administering a therapeutically effective amount of a compound according to claim 1 , where the compound includes a therapeutically effective radioisotope.
6. A kit comprising a compound according to claim 1 .
7. The compound of claim 1 , comprising a chelated metal selected from the group consisting of Tc-94m, Tc-99m, In-111, Ga-67, Ga-68, Y-86, Y-90, Lu-177, Re-186, Re-188, Cu-64, Cu-67, Co-55, Co-57, Sc-47, Ac-225, Bi-213, Bi-212, Pb-212, Sm-153, Ho-166, and Dy-166.